Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AbbVie misses sales estimates on Humira weakness, shares fall

Published 04/29/2022, 07:49 AM
Updated 04/29/2022, 10:36 AM
© Reuters. FILE PHOTO: A woman holds a test tube in front of displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

© Reuters. FILE PHOTO: A woman holds a test tube in front of displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

By Manas Mishra

(Reuters) -AbbVie Inc missed Wall Street estimates for first-quarter sales, hurt by European competition for its blockbuster drug Humira and lower demand for its newer drug Rinvoq, sending shares of the company down 7% on Friday.

Sales of the rheumatoid arthritis drug, Humira, fell 2.7% to $4.74 billion in the first quarter, below estimates of $4.91 billion, as it faces competition from cheaper biosimilar copies in Europe. U.S. rivals are expected next year when it loses patent protection in the country.

"Growth is going to be suppressed in 2023 and somewhat in 2024. But as soon as that pressure is off, that's when we'll re-emerge and deliver growth on the other side," said Chief Executive Officer Richard Gonzalez.

Sales of Rinvoq, one of the drugs AbbVie (NYSE:ABBV) has been betting on to drive growth post 2023, missed estimates in the quarter as the U.S. health regulator issued narrower guidelines in December.

Rinvoq brought in sales of $465 million, below estimates of $500.6 million.

However, plaque psoriasis drug Skyrizi brought in sales of $940 million, beating estimates by nearly $24 million.

Last year, AbbVie completed its $63 billion purchase of Botox-maker Allergan (NYSE:AGN), a move to diversify its portfolio ahead of Humira's loss of exclusivity.

Botox sales in cosmetic applications rose 34.4% to $641 million, breezing past estimates of $569.88 million.

Net revenues of $13.54 billion missed Refinitiv IBES estimates of $13.61 billion.

© Reuters. FILE PHOTO: A woman holds a test tube in front of displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

At the request of the U.S. Securities and Exchange Commission, several drug companies have adjusted their forecasts to include expenses from milestone payments and acquisitions.

AbbVie lowered its adjusted earnings per share forecast to between $13.92 and $14.12, from earlier estimates of $14.00 to $14.20, citing the impact of those expenses.

Latest comments

Buy oh buy the effing dip on this.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.